Liver pathology in morbidly obese patients with and without diabetes
- PMID: 2220728
Liver pathology in morbidly obese patients with and without diabetes
Abstract
The contribution of obesity and/or diabetes to liver pathology in the morbidly obese patient is controversial. We studied the liver biopsies of 100 consecutive patients undergoing gastric bypass surgery for morbid obesity. Multiple morphologic parameters were analyzed and graded independently, without knowledge of the clinical history, liver function tests, and oral glucose tolerance results of the patients. Six percent of the entire group demonstrated no fat, 42% mild fat, 20% moderate fat, and 24% severe fatty metamorphosis of the liver. Twenty-three percent of the patients had central vein fibrosis, 23% sinusoidal fibrosis, 19% bridging fibrosis, and 4% cirrhosis. Thirty-six percent of the patients had some degree of steatohepatitis, 66% possessed so-called glycogen nuclei of hepatocytes, 6% had PAS-positive thickening of blood vessels in the portal tracts, and 1% had lipogranulomas. The degree of fatty metamorphosis and fibrosis was analyzed in three separate groups, categorized by the glycemic status of the patient: 46 patients with normal glucose tolerance (NGT), 23 patients with impaired glucose tolerance (IGT), and 31 patients with non-insulin-dependent diabetes mellitus (NIDDM). Increasing severity of fatty metamorphosis from the normoglycemic obese to the diabetic obese patients was found, which was statistically significant by chi 2 analysis. Four of the six patients showing no fatty metamorphosis were normoglycemic. Glycogen nuclei and PAS-positive blood vessels were significantly more prevalent in the diabetic obese than in the normal obese. In conclusion, the distribution of significant liver histopathology in the morbidly obese patient correlates in severity with the degree of impaired glycemic status.
Comment in
-
Liver pathology and diabetes mellitus.Am J Gastroenterol. 1992 Mar;87(3):404-5. Am J Gastroenterol. 1992. PMID: 1539587 No abstract available.
Similar articles
-
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.Obes Surg. 2006 Dec;16(12):1584-93. doi: 10.1381/096089206779319392. Obes Surg. 2006. PMID: 17217634
-
Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery.Arch Surg. 2003 Nov;138(11):1240-4. doi: 10.1001/archsurg.138.11.1240. Arch Surg. 2003. PMID: 14609874
-
Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery.Obes Surg. 2002 Feb;12(1):49-51. doi: 10.1381/096089202321144577. Obes Surg. 2002. PMID: 11868297
-
Fatty liver disease in morbid obesity.Gastroenterol Clin North Am. 1987 Jun;16(2):239-52. Gastroenterol Clin North Am. 1987. PMID: 3319904 Review.
-
Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations.Pathol Annu. 1989;24 Pt 1:275-302. Pathol Annu. 1989. PMID: 2654841 Review. No abstract available.
Cited by
-
Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease.Curr Hepatol Rep. 2019 Dec;18(4):455-472. doi: 10.1007/s11901-019-00499-5. Epub 2019 Nov 15. Curr Hepatol Rep. 2019. PMID: 36397965 Free PMC article.
-
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. doi: 10.1038/s41575-021-00502-9. Epub 2021 Sep 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34508238 Review.
-
Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.Trends Pharmacol Sci. 2017 Jul;38(7):649-665. doi: 10.1016/j.tips.2017.04.004. Epub 2017 May 24. Trends Pharmacol Sci. 2017. PMID: 28551355 Free PMC article. Review.
-
Chronic Liver Disease-Associated Hospitalizations Among Adults with Diabetes, National Inpatient Sample, 2001-2012.Public Health Rep. 2015 Nov-Dec;130(6):693-703. doi: 10.1177/003335491513000619. Public Health Rep. 2015. PMID: 26556941 Free PMC article.
-
Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat.Environ Health Prev Med. 2012 Nov;17(6):444-56. doi: 10.1007/s12199-012-0273-y. Epub 2012 Mar 11. Environ Health Prev Med. 2012. PMID: 22407906 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical